# EU Panel Again Declines to Endorse Omeros Transplant Therapy

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/33450
Published: 2026-10-16T19:55:22.000Z
Updated: 2026-10-16T19:55:22.000Z
Section: Regulation

> Omeros had also failed to secure the panel’s backing in an earlier review this year.

For a second time in 2026, an expert panel at the European Medicines Agency (EMA) declined to endorse narsoplimab, Omeros Corporation’s transplant therapy.

Omeros, a Seattle-based biotech, had also not secured the panel’s backing in an earlier review this year.